ecrin-mdr-crcClinical2011AdenocarcinomaRecurrent Colon CancerAdenocarcinoma of the RectumRectal NeoplasmsStage IV Rectal CancerColorectal NeoplasmsStage IV Colon CancerRecurrent Rectal CancerColonic NeoplasmsNeoplasmsAdenocarcinoma of the ColonStage Iv Colon CancerAdenocarcinomaRecurrent Colon CancerRectal NeoplasmsStage Iv Rectal CancerAdenocarcinoma Of The RectumColorectal NeoplasmsAdenocarcinoma Of The ColonRecurrent Rectal CancerColonic NeoplasmsNeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2102201United States2Neoplasms by SiteGastrointestinal DiseasesGastrointestinal NeoplasmsRectal DiseasesHSP90 Heat-Shock ProteinsIntestinal DiseasesEGFR protein, humanDigestive System DiseasesCetuximabIntestinal NeoplasmsColonic DiseasesDigestive System NeoplasmsECRIN MDRCompletedfalseStudy of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal CancerThe study will determine the maximum tolerated dose (MTD) of AUY922 given in combination with cetuximab in previously treated patients with KRAS wild-type metastatic colorectal cancer.2011-02-152102201NCT01294826